MIDLOTHIAN, Va., Sept. 29, 2021 /PRNewswire/ -- Pulmotect reported positive topline results from their randomized, placebo-controlled Phase-2 trial of PUL-042 against COVID-19. Patients treated with ...
MIDLOTHIAN, Va., May 7, 2020 /PRNewswire/ -- This week, the first patients are enrolling in two phase 2 clinical trials for COVID-19 using Pulmotect's PUL-042, an inhaled immunomodulatory agent to ...
MIDLOTHIAN, Va., Oct. 22 In the October supplement of USRespiratory Report, Dr. Donald Tashkin will follow-up his significant studycomparing the effectiveness of nebulizers and metered dose inhalers ...
- ARIKAYCE is the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options - ...
MIDLOTHIAN, Va., March 10 PARI's LC STAR nebulizer andPRONEB Ultra II compressor are the exclusive delivery devices for InspirePharmaceuticals' (Nasdaq: ISPH) second Phase 3 clinical trial for a ...
STARNBERG, Germany, June 7, 2016 /PRNewswire/ -- PARI Pharma, a company focused on the development of advanced aerosol therapies using eFlow Technology, announces that its proprietary closed eFlow ...
As highlighted in the April issue of Medical Device & Diagnostic Industry magazine, PARI Aerosol Research Institute has been awarded a 2006 Medical Design Excellence Award for eFlow. eFlow is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback